P16_37-63 + Montanide ISA-51 VG

**P16_37-63 + Montanide ISA-51 VG** is a therapeutic cancer vaccine candidate composed of a synthetic peptide (corresponding to amino acids 37-63 of the human p16 protein) formulated with the adjuvant Montanide ISA-51 VG. The peptide acts as a tumor antigen designed to elicit a specific immune response against p16-expressing tumor cells. Montanide ISA-51 VG is an oil-based immunological adjuvant that enhances immune responses by forming a water-in-oil emulsion, sustaining antigen release and stimulating both T-cell and antibody responses. This combination is primarily developed for use in immunotherapy vaccine trials, notably for solid tumors that overexpress p16. Montanide ISA-51 VG is developed and manufactured by Seppic. The primary mechanism of action is activation and amplification of anti-tumor immune responses through enhanced antigen presentation and immune cell recruitment[1][2][3][4].

Other names

P16_37-63 peptide vaccine + Montanide ISA-51 VGP16 peptide (amino acids 37-63) + Montanide ISA-51 VGP16_37-63/Montanide ISA-51 VG